Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2B 〉TSH Biopharm Co., Ltd.

TSH Biopharm Co., Ltd.

Chat Now My Favorites
      Chronic disease is one of the most important issues related to life expectancy and modern civilization. It is also the niche market TSH Biopharm devotes itself to; we focus on cardiovascular and autoimmune disease, and we contribute to patients, medical institutions and society constantly by developing patentable and high-barrier specialty drugs that have a pharmacoeconomics profile.

      Our theory of business is to focus on both ends of the smile curve of the pharmaceutical value chain: Development and marketing. Our market strategy is to use Taiwan as a base to expand to mainland Asia and then the global market; our R&D team develops slow release compound and biosimilar drugs in this order and overcomes the product differentiation barrier, balances operating profits, research and innovation, and allows all shareholders to profit and to be involved in the development.

      Currently, TSH Biopharm has several R&D projects in progress, and it highly focuses on the research and development, and it highly focuses on the research and development of cardiovascular, auto-immune and gastrointestinal drugs.

      In Taiwan, the generic pharmaceutical industry is highly competitive due to decreasing National Health Insurance price and increasing costs of products with PIC/S qualification, which seriously affect profits. Most of our products are in differentiated dosage form, and the processes are in compliance with PIC/S and GMP, which are able to maintain a generally stable and competitive price on the basis of the annual price adjustment principle of National Health Insurance drug payments.
Below is our marketing strategy:
Management Plan: To integrate the pharmaceutical value chain by implementation of our company strategy and development of
our own products, establish a patent portfolio, and focus on Taiwan and the global market.
Product Strategy: To cooperate with manufacturers approved by PIC/S GMP, produce high-quality products, and create
high value-added research and marketing.
Marketing Strategy: Based in Taiwan, to develop markets for chronic diseases in Taiwan and China through the development of patents and high-barrier specialty drugs.
R&D Strategy: To focus on developing cardiovascular and autoimmune disease drugs, and establish the ability to create products with global qualification.

      Other than treatments TSH Biopharm work with CellMax to offer Personal diagnosis service for Cancer risk assessment, Cancer diagnosis, and Progression monitoring. All the tests are performed in CLIA and CAP certified laboratory with proprietary Technologies. New tests are underdeveloped to cover more cancer types and other disease areas. 

      Organization and individual talent are our cornerstones; our business grows by establishing an internal education system with TSH Biopharm's unique culture: Professionalism and Entrepreneurship, which give our organization heart and spirit, tempering and growing it continuously.

      Recently, we have made an effort to develop product globalization. We are looking forward to achieving this goal and creating maximum value for our employees and shareholders.

      For more information about TSH Biopharm Co. Ltd., please visit:http://www.tshbiopharm.com/webls-en-us/index.html
  • Grace Yang/ General Manager

    Grace Yang/ General Manager

    Confirm short and long term goals, plan and organize development direction, find strategic partners and ensure corporate performance.
  • Leon Liao/BD Director

    Leon Liao/BD Director

    Responsible for overseas company management, strategic alliances, new ventures, external cooperation and M&A strategies.
  • Catherine Wu/ M&S Director

    Catherine Wu/ M&S Director

    Develop strategy in accordance with company disease category, integrate marketing business resources, implement marketing strategies before new products launch, promote prescription drugs.
  • Stacy Sun/ Administration Director

    Stacy Sun/ Administration Director

    Integrate administration resource in accordance with short and long term goals of TSH.
  • Joyce Kan/ Financial Manager

    Joyce Kan/ Financial Manager

    Implement the company's accounting and financial management.
      Chronic disease is one of the most important issues related to life expectancy and modern civilization. It is also the niche market TSH Biopharm devotes itself to; we focus on cardiovascular and autoimmune disease, and we contribute to patients, medical institutions and society constantly by developing patentable and high-barrier specialty drugs that have a pharmacoeconomics profile.

      Our theory of business is to focus on both ends of the smile curve of the pharmaceutical value chain: Development and marketing. Our market strategy is to use Taiwan as a base to expand to mainland Asia and then the global market; our R&D team develops slow release compound and biosimilar drugs in this order and overcomes the product differentiation barrier, balances operating profits, research and innovation, and allows all shareholders to profit and to be involved in the development.

      Currently, TSH Biopharm has several R&D projects in progress, and it highly focuses on the research and development, and it highly focuses on the research and development of cardiovascular, auto-immune and gastrointestinal drugs.

      In Taiwan, the generic pharmaceutical industry is highly competitive due to decreasing National Health Insurance price and increasing costs of products with PIC/S qualification, which seriously affect profits. Most of our products are in differentiated dosage form, and the processes are in compliance with PIC/S and GMP, which are able to maintain a generally stable and competitive price on the basis of the annual price adjustment principle of National Health Insurance drug payments.
Below is our marketing strategy:
Management Plan: To integrate the pharmaceutical value chain by implementation of our company strategy and development of
our own products, establish a patent portfolio, and focus on Taiwan and the global market.
Product Strategy: To cooperate with manufacturers approved by PIC/S GMP, produce high-quality products, and create
high value-added research and marketing.
Marketing Strategy: Based in Taiwan, to develop markets for chronic diseases in Taiwan and China through the development of patents and high-barrier specialty drugs.
R&D Strategy: To focus on developing cardiovascular and autoimmune disease drugs, and establish the ability to create products with global qualification.

      Other than treatments TSH Biopharm work with CellMax to offer Personal diagnosis service for Cancer risk assessment, Cancer diagnosis, and Progression monitoring. All the tests are performed in CLIA and CAP certified laboratory with proprietary Technologies. New tests are underdeveloped to cover more cancer types and other disease areas. 

      Organization and individual talent are our cornerstones; our business grows by establishing an internal education system with TSH Biopharm's unique culture: Professionalism and Entrepreneurship, which give our organization heart and spirit, tempering and growing it continuously.

      Recently, we have made an effort to develop product globalization. We are looking forward to achieving this goal and creating maximum value for our employees and shareholders.

      For more information about TSH Biopharm Co. Ltd., please visit:http://www.tshbiopharm.com/webls-en-us/index.html